SAGE BIONETWORKS: Form 990, tax year 2018
View the entire original 990 at ProPublica ↗
- Organization
- SAGE BIONETWORKS (EIN 26-4489946)
- Tax period
- 2018-01-01 to 2018-12-31
- Filed
- 2019-10-15
- IRS object ID
- 201922899349300212
- Schema version
- 2018v3.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Reasonable Cause Explanation
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2019-10-15T09:45:17-07:00 | ReturnTs |
| Tax Period End | 2018-12-31 | TaxPeriodEndDt |
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2018-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 264489946 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | SAGE BIONETWORKS | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | SAGE | BusinessNameControlTxt |
| Phone | 2069288250 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2901 Third Ave Ste 330 | AddressLine1Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | Lara Mangravite | PersonNm |
| Person Title | President | PersonTitleTxt |
| Phone | 2069288250 | PhoneNum |
| Signature | 2019-10-15 | SignatureDt |
Filing Security Information FilingSecurityInformation
IP Address IPAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| I Pv4 Address | 207.109.76.122 | IPv4AddressTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2018 | TaxYr |
| Build TS | 2019-02-21 02:37:17Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | Lara Mangravite | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2901 Third Ave | AddressLine1Txt |
| Address Line2 | Ste 330 | AddressLine2Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $17,958,815 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | www.sagebionetworks.org | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2009 | FormationYr |
| Legal Domicile State | WA | LegalDomicileStateCd |
| Activity Or Mission | Sage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement. | ActivityOrMissionDesc |
| Voting Members Governing Body | 6 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 5 | VotingMembersIndependentCnt |
| Total Employee | 71 | TotalEmployeeCnt |
| Total Volunteers | 5 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $7,337,401 | PYContributionsGrantsAmt |
| CY Contributions Grants | $15,555,426 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $3,001,123 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $2,402,775 | CYProgramServiceRevenueAmt |
| PY Investment Income | $258 | PYInvestmentIncomeAmt |
| CY Investment Income | $614 | CYInvestmentIncomeAmt |
| PY Other Revenue | $0 | PYOtherRevenueAmt |
| CY Other Revenue | $0 | CYOtherRevenueAmt |
| PY Total Revenue | $10,338,782 | PYTotalRevenueAmt |
| CY Total Revenue | $17,958,815 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $786,047 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $1,886,803 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $6,762,079 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $8,601,831 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $40,673 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $3,456,621 | PYOtherExpensesAmt |
| CY Other Expenses | $4,233,682 | CYOtherExpensesAmt |
| PY Total Expenses | $11,004,747 | PYTotalExpensesAmt |
| CY Total Expenses | $14,722,316 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$665,965 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $3,236,499 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $3,193,164 | TotalAssetsBOYAmt |
| Total Assets EOY | $5,921,898 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $1,753,320 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $1,245,555 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $1,439,844 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $4,676,343 | NetAssetsOrFundBalancesEOYAmt |
| Mission | Sage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement. Sage Bionetworks is a non-profit research organization that seeks to develop predictors of disease and accelerate health research through the creation of open systems, incentives, and standards. We create strategies and platforms that empower researchers to share and interpret data on a colossal scale, crowdsource tests for new hypotheses, and contribute to knowledge through community challenges. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $9,647,005 | ExpenseAmt |
| Grant | $7,068,028 | GrantAmt |
| Revenue | $10,893,528 | RevenueAmt |
| Desc | Research Communities and Challenges: Sage Bionetworks conducts research independently as well as with collaborators worldwide across a variety of disease areas. We work to redefine how complex biological data is gathered, shared and used through open systems, incentives, and norms. Our work includes the building of platforms and services and undertaking research developing predictors relating to health. Research: As biological research has become more data intensive, the breadth of data and expertise required to address research problems has expanded. It requires the integrated efforts of a distributed set of researchers (such as bench/data scientists, data engineers, project managers, administrators, governance experts, and clinical researchers) with shared interests and complementary resources. Effective collaboration depends on a collective ability to work together in trusted ways that lead to translatable biomedical insights. We call this scientific coordination. Sage's scientific coordination stack includes: 1) hypothesis and data generation, 2) data curation, 3) analysis, 4) interpretation, and 5) dissemination. We focus on building a federated network of individuals who bring diverse expertise and approaches to develop robust solutions. New research projects initiated in 2018 included: * Human Tumor Atlas Network (HTAN) - Funded by NCI, Sage is the data coordinating center for HTAN which aims to leverage the power of human genome sequencing and other state-of-the-art profiling technologies, to analyze changes in individual tumors. * VEOIBD Portal - Funded by the Helmsley Charitable Trust, the VEOIBD Portal aggregates Consortium-identified genotypic data with data from other data sources to find causes and treatments for Inflammatory Bowel Disease (IBD). Ongoing research communities included: * Agora - funded by the NIA, Agora is a platform that enables researchers to access information about how genes are associated with Alzheimer's disease. It aggregates lines of biological evidence from multiple sources, so researchers can better prioritize which genes they want to follow up on for development of new therapies. * All of Us - a program to engage over one million participants in a study to improve the ability to prevent and treat disease based on individual differences in lifestyle, environment and genetics. * CD2H (National Center for Data to Health) - with aims to foster collaboration across more than 50 premier medical research institutions within the prestigious Clinical and Translational Science Awards, or CTSA, network. * Cancer Systems Biology Consortium (CSBC) - Sage serves as the Coordinating Center for the CSBC and Physical Sciences in Oncology Network (PS-ON) program. This five-year award builds on the work of the NCI funded Sage Bionetworks' Center for Cancer Systems Biology from 2010 through 2015. * iAtlas -together with the Institute for Systems Biology, Sage was funded by the Cancer Research Institute to build iAtlas, an online database and web resource designed to help basic and clinical researchers navigate immunological data across multiple tumor types. * KiAAP - funded by Bill and Melinda Gates Foundation, Sage was engaged to support the distributed efforts of BMGF funded data scientists across a number of ongoing research projects in neurocognitive development. * MODEL-AD Consortium - Sage runs the Knowledge Portal, the distribution site for data, analysis results, analytical methodology and research tools generated by the AMP-AD and M2OVE-AD Consortia. * Synodos Consortium - a first-of-its-kind Neurofibromatosis research collaboration dedicated to defeating the rare genetic disorder neurofibromatosis type 2. * The Cancer Genome Atlas (TCGA) - with data from 12 cancers, TCGA is an ongoing effort to simultaneously analyze molecular platforms for patterns across cancer types. * Tumor Neoantigen Selection Alliance (TESLA) - a global research alliance with 30 public and private groups to advance the development of more effective personalized cancer treatments. Funded by the Parker Institute for Cancer. Challenges: With algorithms playing an increasing role in biomedical analysis and patient care, there's a need for a more rigorous framework for evaluating and improving the capabilities of these algorithms. Sage Bionetworks has pioneered the development of concepts and infrastructure to objectively evaluate algorithms across a broad spectrum of biomedical domains, including bioinformatics, biomedical informatics, and clinical trials. As a trusted partner in hosting challenges and benchmarking initiatives, Sage serves as a broker between data generators and data modelers. We combine technology with biomedical and data science expertise to facilitate the objective assessment of algorithms on critical data sets, including proprietary data and algorithms that cannot be broadly shared. Sage works with the DREAM community to host open challenges. With 13 years of successful Challenges, DREAM is recognized as a leader in biomedical competitions, successfully motivating research teams to address fundamental questions about systems biology and translational medicine and to advance computational methods. DREAM challenges invite participants to propose solutions - fostering collaboration and building communities in the process. Over 20,000 people from around the world and across disciplines have contributed their expertise to Challenges. Sage Bionetworks provides institutional support, along with the infrastructure to host challenges via our Synapse platform Active Challenges hosted on the Synapse platform in 2018 included: * ACIC 2018 Causal Inference Challenge -held at the annual Atlantic Causal Inference Conference (ACIC), participants of this challenge focused on computational methods of inferring causal effects from real-world healthcare-related data. * DREAM Single Cell Transcriptomics Challenge - participants were asked to reconstruct the location of single cells in the Drosophila embryo using single-cell transcriptomic data. * IDG Drug-Kinase Binding Challenge - seeks to evaluate the power of statistical and machine learning models as a systematic and cost-effective means for catalyzing compound-target interaction mapping efforts. * Multi-targeting Drug DREAM Challenge - seeks to diversify the methods used for rational design of drugs with multiple target proteins. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $4,414,233 | ExpenseAmt |
| Grant | $3,554,233 | GrantAmt |
| Revenue | $4,984,896 | RevenueAmt |
| Desc | Digital Health Smartphones and other wearable sensors have put touchscreens and high-fidelity sensors into the pockets of billions of people. These technologies provide an opportunity to paint a rich understanding of health and disease in the everyday world outside of the clinic. They also provide communication tools that allow participants a more active voice in research programs. With our Digital Health program, we work to advance health research through practices that support the design, development and implementation of studies that use technology to monitor health outside of the clinical setting, and the analysis and sharing of the resulting study data. We help to derive and test digital biomarkers. We evaluate analytical methodologies to benchmark best practices in study design and data analysis. Sage's Digital Health program is built around Bridge, a technology platform for conducting biomedical research studies primarily using the ResearchKit (iOS) and ResearchStack (Android) frameworks. Bridge is composed of HIPAA-compliant web services and multi-language SDKs that facilitate: registration and informed consent to participate in research; web-based tools to design and schedule study surveys and sensor-based tasks; acquisition and secure transfer of multiple data types (surveys, sensors, audio, video, or custom data types); a study management portal with daily dashboard updates; and de-identification and storage of study data in our collaborative data science environment, Synapse. Digital Health studies active in 2018 included: * Cardiovascular Fitness Module - As part of the PMI All of Us study, Sage is developing methods to use the sensors built into smartphones to assess Cardiorespiratory fitness in a way that can scale to potentially one million participants and become a generally useful tool for clinical research. * Chronic Anemia - conducted in partnership with Celgene, Journey PRO incorporates wearable and mobile technologies to assess mobility, cardiovascular health, cognitive performance, and quality of life assessments. * Multiple Sclerosis - with pharmaceutical partner Novartis, Sage launched elevateMS, a mobile app to monitor the severity of MS symptoms and to track relapse * Sage, together with study partners at OHSU, publicly released the first data set from the Mole Mapper melanoma mobile health study. * mPower Public Researcher Portal - an updated version of the mPower iPhone study piloting new approaches to monitoring key indicators of Parkinson Disease was active in 2018. A subset of data from this portal along with data contributed by MJFF was included in the PD Digital Biomarker DREAM Challenge launched in 2017. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $0 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $0 | TotalOtherProgSrvcGrantAmt |
| Total Other Prog Srvc Revenue | $0 | TotalOtherProgSrvcRevenueAmt |
| Total Program Service Expenses | $14,061,238 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | 0 | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | 0 | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | Yes (1) | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 19 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Employee | 71 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 6 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 5 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | 0 | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | 0 | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | Diane Gary | PersonNm |
| Phone | 2069288243 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2901 Third Ave Ste 330 | AddressLine1Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (16 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | OfficerOfficerInd | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| Stephen Friend | |||||||||
| Chairman of the Board | 1 | Yes (X) | $0 | $0 | $0 | ||||
| Eric Schadt | |||||||||
| Director/Chair of Scientific Advisory Board | 1 | Yes (X) | $0 | $0 | $0 | 0 | |||
| Tony Ford-Hutchinson | |||||||||
| Director | 1 | Yes (X) | $0 | $0 | $0 | 0 | |||
| Gustavo Stolovitsky | |||||||||
| Director | 1 | Yes (X) | $0 | $0 | $0 | 0 | |||
| Tetsu Maruyama | |||||||||
| Director | 1 | Yes (X) | $0 | $0 | $0 | 0 | |||
| Lara Mangravite | |||||||||
| President | 50 | $245,496 | $0 | $36,644 | 0 | Yes (X) | |||
| Diane Gary | |||||||||
| Secretary | 50 | $166,446 | $0 | $30,837 | 0 | Yes (X) | |||
| John Wilbanks | |||||||||
| Chief Commons Officer | 50 | $231,848 | $0 | $21,981 | 0 | Yes (X) | |||
| Mike Kellen | |||||||||
| Chief Technology Officer | 50 | $210,759 | $0 | $23,947 | 0 | Yes (X) | |||
| Justin Guinney | |||||||||
| Vice President, Computational Oncology | 50 | $195,821 | $0 | $36,057 | 0 | Yes (X) | |||
| Larsson Omberg | |||||||||
| Vice President, Systems Biology | 50 | $166,446 | $0 | $30,832 | 0 | Yes (X) | |||
| Bruce Hoff | |||||||||
| Director, Synapse Team | 50 | $166,334 | $0 | $39,614 | 0 | Yes (X) | |||
| Erin Mounts | |||||||||
| Principle SW Engineer | 50 | $161,735 | $0 | $30,504 | 0 | Yes (X) | |||
| Dwayne Jeng | |||||||||
| Principal SW Engineer | 50 | $156,897 | $0 | $19,987 | 0 | Yes (X) | |||
| Alx Dark | |||||||||
| Principle Software Engineer | 50 | $156,811 | $0 | $11,529 | 0 | Yes (X) | |||
| John Woodburn | |||||||||
| Director, Design | 50 | $154,831 | $0 | $19,835 | 0 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $2,013,424 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $301,767 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 39 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (2 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| Stockard Simon | |||||
| 44564 SE 144th St | North Bend | WA | 98045 | IT Design | $152,386 |
| Yuangang Guan | |||||
| 744 Eagle Ave | Ann Arbor | MI | 48103 | Scientific challenges | $113,917 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 2 | CntrctRcvdGreaterThan100KCnt |
| Federated Campaigns | $0 | FederatedCampaignsAmt |
| Membership Dues | $0 | MembershipDuesAmt |
| Fundraising | $0 | FundraisingAmt |
| Related Organizations | $0 | RelatedOrganizationsAmt |
| Government Grants | $10,622,261 | GovernmentGrantsAmt |
| All Other Contributions | $4,933,165 | AllOtherContributionsAmt |
| Noncash Contributions | $101,355 | NoncashContributionsAmt |
| Total Contributions | $15,555,426 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | Scientific Collaborations | Desc |
| Business | 541711 | BusinessCd |
| Total Revenue Column | $2,402,775 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $2,402,775 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $0 | ExclusionAmt |
Total Oth Program Service Rev TotalOthProgramServiceRevGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $0 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $2,402,775 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $614 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $614 | ExclusionAmt |
Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $0 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $0 | ExclusionAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $0 | RealAmt |
| Personal | $0 | PersonalAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $0 | SecuritiesAmt |
| Other | $0 | OtherAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contri Rpt Fundraising Event | $0 | ContriRptFundraisingEventAmt |
| Other Revenue Total | $0 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $17,958,815 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $2,402,775 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $614 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,660,903 | TotalAmt |
| Program Services | $1,660,903 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $225,900 | TotalAmt |
| Program Services | $225,900 | ProgramServicesAmt |
Benefits To Members BenefitsToMembersGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,465,680 | TotalAmt |
| Program Services | $1,218,969 | ProgramServicesAmt |
| Management And General | $235,992 | ManagementAndGeneralAmt |
| Fundraising | $10,719 | FundraisingAmt |
Comp Disqual Persons CompDisqualPersonsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,733,150 | TotalAmt |
| Program Services | $5,505,292 | ProgramServicesAmt |
| Management And General | $209,658 | ManagementAndGeneralAmt |
| Fundraising | $18,200 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $232,559 | TotalAmt |
| Program Services | $217,633 | ProgramServicesAmt |
| Management And General | $14,278 | ManagementAndGeneralAmt |
| Fundraising | $648 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $919,508 | TotalAmt |
| Program Services | $893,899 | ProgramServicesAmt |
| Management And General | $23,077 | ManagementAndGeneralAmt |
| Fundraising | $2,532 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $250,934 | TotalAmt |
| Program Services | $232,870 | ProgramServicesAmt |
| Management And General | $17,341 | ManagementAndGeneralAmt |
| Fundraising | $723 | FundraisingAmt |
Fees For Services Management FeesForServicesManagementGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $62,696 | TotalAmt |
| Program Services | $58,815 | ProgramServicesAmt |
| Management And General | $3,643 | ManagementAndGeneralAmt |
| Fundraising | $238 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $138,472 | TotalAmt |
| Program Services | $129,901 | ProgramServicesAmt |
| Management And General | $8,045 | ManagementAndGeneralAmt |
| Fundraising | $526 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $38,737 | TotalAmt |
| Program Services | $36,339 | ProgramServicesAmt |
| Management And General | $2,251 | ManagementAndGeneralAmt |
| Fundraising | $147 | FundraisingAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Fundraising | $0 | FundraisingAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,372,299 | TotalAmt |
| Program Services | $2,355,780 | ProgramServicesAmt |
| Management And General | $15,505 | ManagementAndGeneralAmt |
| Fundraising | $1,014 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $49,173 | TotalAmt |
| Program Services | $46,129 | ProgramServicesAmt |
| Management And General | $2,857 | ManagementAndGeneralAmt |
| Fundraising | $187 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $160,055 | TotalAmt |
| Program Services | $150,148 | ProgramServicesAmt |
| Management And General | $9,299 | ManagementAndGeneralAmt |
| Fundraising | $608 | FundraisingAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $605,854 | TotalAmt |
| Program Services | $568,352 | ProgramServicesAmt |
| Management And General | $35,200 | ManagementAndGeneralAmt |
| Fundraising | $2,302 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $364,570 | TotalAmt |
| Program Services | $341,123 | ProgramServicesAmt |
| Management And General | $22,008 | ManagementAndGeneralAmt |
| Fundraising | $1,439 | FundraisingAmt |
Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $38,378 | TotalAmt |
| Program Services | $37,287 | ProgramServicesAmt |
| Management And General | $1,024 | ManagementAndGeneralAmt |
| Fundraising | $67 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Payments To Affiliates PaymentsToAffiliatesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $16,806 | TotalAmt |
| Program Services | $15,766 | ProgramServicesAmt |
| Management And General | $976 | ManagementAndGeneralAmt |
| Fundraising | $64 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $29,139 | TotalAmt |
| Program Services | $27,335 | ProgramServicesAmt |
| Management And General | $1,693 | ManagementAndGeneralAmt |
| Fundraising | $111 | FundraisingAmt |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $357,503 | TotalAmt |
| Program Services | $338,797 | ProgramServicesAmt |
| Management And General | $17,558 | ManagementAndGeneralAmt |
| Fundraising | $1,148 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $14,722,316 | TotalAmt |
| Program Services | $14,061,238 | ProgramServicesAmt |
| Management And General | $620,405 | ManagementAndGeneralAmt |
| Fundraising | $40,673 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $488,278 | BOYAmt |
| EOY | $564,479 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,570,019 | BOYAmt |
| EOY | $3,134,674 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $46,969 | BOYAmt |
| EOY | $1,021,718 | EOYAmt |
Receivables From Officers Etc ReceivablesFromOfficersEtcGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $84,143 | BOYAmt |
| EOY | $88,014 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $104,503 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $13,208 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,755 | BOYAmt |
| EOY | $91,295 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Investments Program Related InvestmentsProgramRelatedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Intangible Assets IntangibleAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $1,021,718 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,193,164 | BOYAmt |
| EOY | $5,921,898 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $759,381 | BOYAmt |
| EOY | $750,306 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $993,939 | BOYAmt |
| EOY | $457,667 | EOYAmt |
Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Escrow Account Liability EscrowAccountLiabilityGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Loans From Officers Directors LoansFromOfficersDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $37,582 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,753,320 | BOYAmt |
| EOY | $1,245,555 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,280,854 | BOYAmt |
| EOY | $2,352,896 | EOYAmt |
Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $158,990 | BOYAmt |
| EOY | $2,323,447 | EOYAmt |
Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,439,844 | BOYAmt |
| EOY | $4,676,343 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,193,164 | BOYAmt |
| EOY | $5,921,898 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $3,236,499 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $0 | NetUnrlzdGainsLossesInvstAmt |
| Donated Services And Use Fclts | $0 | DonatedServicesAndUseFcltsAmt |
| Investment Expense | $0 | InvestmentExpenseAmt |
| Prior Period Adjustments | $0 | PriorPeriodAdjustmentsAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | Yes (1) | AccountantCompileOrReviewInd |
Acct Compile Or Review Basis AcctCompileOrReviewBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $7,808,314 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $6,230,203 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $5,050,380 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $7,337,399 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $12,490,269 | CurrentTaxYearAmt |
| Total | $38,916,565 | TotalAmt |
Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $0 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $0 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $0 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $0 | CurrentTaxYearMinus1YearAmt |
| Total | $0 | TotalAmt |
Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $0 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $0 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $0 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $0 | CurrentTaxYearMinus1YearAmt |
| Total | $0 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $7,808,314 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $6,230,203 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $5,050,380 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $7,337,399 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $12,490,269 | CurrentTaxYearAmt |
| Total | $38,916,565 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Support Total170 | $38,916,565 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,802 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,056 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $380 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $258 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $614 | CurrentTaxYearAmt |
| Total | $4,110 | TotalAmt |
Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $0 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $0 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $0 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $0 | CurrentTaxYearMinus1YearAmt |
| Total | $0 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,552,869 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,464,542 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $2,230,377 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $3,001,123 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $2,402,778 | CurrentTaxYearAmt |
| Total | $10,651,689 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $49,572,364 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $0 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.78505 | PublicSupportCY170Pct |
| Public Support PY170 | 0.76345 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule A, Part II, Line 10 | FormAndLineReferenceDesc |
| Explanation | Fee for service revenue from research collaborations. | ExplanationTxt |
Schedule B IRS990ScheduleB
Schedule D IRS990ScheduleD
Land LandGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Investment Cost Or Other Basis | $0 | InvestmentCostOrOtherBasisAmt |
| Other Cost Or Other Basis | $0 | OtherCostOrOtherBasisAmt |
| Book Value | $0 | BookValueAmt |
Buildings BuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Investment Cost Or Other Basis | $0 | InvestmentCostOrOtherBasisAmt |
| Other Cost Or Other Basis | $0 | OtherCostOrOtherBasisAmt |
| Depreciation | $0 | DepreciationAmt |
| Book Value | $0 | BookValueAmt |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Investment Cost Or Other Basis | $0 | InvestmentCostOrOtherBasisAmt |
| Other Cost Or Other Basis | $0 | OtherCostOrOtherBasisAmt |
| Depreciation | $0 | DepreciationAmt |
| Book Value | $0 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Investment Cost Or Other Basis | $104,503 | InvestmentCostOrOtherBasisAmt |
| Other Cost Or Other Basis | $0 | OtherCostOrOtherBasisAmt |
| Depreciation | $13,208 | DepreciationAmt |
| Book Value | $91,295 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Investment Cost Or Other Basis | $0 | InvestmentCostOrOtherBasisAmt |
| Other Cost Or Other Basis | $0 | OtherCostOrOtherBasisAmt |
| Depreciation | $0 | DepreciationAmt |
| Book Value | $0 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $91,295 | TotalBookValueLandBuildingsAmt |
Other Assets Org OtherAssetsOrgGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | Pledges Receivable, net of current portion | Desc |
| Book Value | $1,021,718 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Other Assets | $1,021,718 | TotalBookValueOtherAssetsAmt |
| Federal Income Tax Liability | $0 | FederalIncomeTaxLiabilityAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | Deferred building rent | Desc |
| Amt | $37,582 | Amt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $37,582 | TotalLiabilityAmt |
| Total Rev Etc Audited Fincl Stmt | $17,958,815 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $0 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $0 | DonatedServicesAndUseFcltsAmt |
| Recoveries Prior Year Grants | $0 | RecoveriesPriorYearGrantsAmt |
| Other Revenue | $0 | OtherRevenueAmt |
| Revenue Not Reported | $0 | RevenueNotReportedAmt |
| Revenue Subtotal | $17,958,815 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $0 | InvestmentExpensesNotIncldAmt |
| Other Revenues Not Included | $0 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $0 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $17,958,815 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $14,722,316 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $0 | DonatedServicesUseFcltsAmt |
| Prior Year Adjustments | $0 | PriorYearAdjustmentsAmt |
| Losses Reported | $0 | LossesReportedAmt |
| Other Expenses Included | $0 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $0 | ExpensesNotReportedAmt |
| Expenses Subtotal | $14,722,316 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $0 | InvestmentExpensesNotIncld2Amt |
| Other Expenses Not Included | $0 | OtherExpensesNotIncludedAmt |
| Expenses Not Rpt Fincl Stmt | $0 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $14,722,316 | TotalExpensesPerForm990Amt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | Europe (including Iceland and Greenland) | RegionTxt |
| Offices | 0 | OfficesCnt |
| Employee | 0 | EmployeeCnt |
| Type Of Activities Conducted | Grantmaking | TypeOfActivitiesConductedTxt |
| Specific Services Provided | Data generation for our Coordinated biocomputational studies. To enable testing of the therapeutic hypothesis, and to further prioritize targets for more extensive drug development programs, we will develop a toolkit of experimental reagents and data - termed a Target Enabling Package (TEP) - for 10 AMP-AD targets. The TEP is meant to bridge the gap between identification of candidate targets, and the ability to launch a chemical biology or drug discovery program. A TEP will typically include purified protein, biochemical assays, crystal structures, and tool compounds. In some cases, the TEP will identify sequences for mutation in CRISPR/Cas9 loss-of function editing, but in most cases it will enable the initiation of a small molecule chemical probe or antibody discovery project by proving that the target is tractable and reducing the barrier to drug discovery. | SpecificServicesProvidedTxt |
| Region Total Expenditures | $225,900 | RegionTotalExpendituresAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Total Spent | $225,900 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (3 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Non Cash AssistanceNonCashAssistanceAmt |
|---|---|---|---|---|
| Europe (including Iceland and Greenland) | To enable testing of the therapeutic hypothesis, and to further prioritize targets for more extensive drug development programs, we will develop a toolkit of experimental reagents and data - termed a Target Enabling Package (TEP) - for 10 AMP-AD targets. All TEP components will be openly distributed as described in the resource sharing plan. Our previous experience of over a dozen TEP programs indicates that the availability of therapeutic hypothesis, evidence of druggability, and initial chemical hits for a new target will tempt a wide spectrum of medicinal chemists to launch more extensive chemical development programs. | $162,928 | Wire Transfer | $0 |
| Europe (including Iceland and Greenland) | Serve as experts in DREAM challenge organization, participate in designing the CTPAC-DREAM Proteogenomics Challenge, testing the challenge by doing the initial analysis (dry run), scoring participants submissions, and performing the sub-challenge metaanalysis of results. | $39,220 | Wire Transfer | $0 |
| Europe (including Iceland and Greenland) | Complete gene expression characterization of CRC cell lines and PDX models as well as in silico pharmacogenetic studies in cell lines. Complete xenotrials in molecularly stratified models and receive most of the clinical molecular data from collaborating pharma/academia clinical trials in order to perform correlative predictive and prognostic analyses. Complete data analysis from xenotrials, treatment biomarker interactions from clinical trials and summarize findings with the "investigator-driven' molecularly stratified clinical trial proposals to run in parallel of the MoTriColor study | $23,752 | Wire Transfer | $0 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 0 | Total501c3OrgCnt |
| Total Other Org | 3 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule F, Part I, Line 2 | FormAndLineReferenceDesc |
| Explanation | Monitoring the use of grant funds: In some cases, grants received by Sage Bionetworks are passed on to sub-recipients through a sub-award agreement. The Grant Manager is responsible for initiating the sub-award agreement after obtaining budget approval from the PI and Operations Director. In issuing a sub-award, the Grant Manager is responsible for: obtaining verification of the sub-awardee's facilities and administrative rates and Single Audit Reports; reviewing the prime award special terms and conditions to determine whether they are applicable to the sub-award; and determining whether the sub-awardee meets all of the other administrative and regulatory requirements of the prime award. Once the sub-award has been issued, the Grant Manager is responsible for forwarding the fully executed sub-award documents to the Accounting Manager to ensure proper billing. Payments are made only after the sub-award agreement has been fully executed by both parties. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (17 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|
| Institute for Systems Biology | ||||||||
| 401 Terry Ave N | Seattle | WA | 98109 | 912003593 | $489,494 | $0 | Assist in the development of an integrative platform: the Pan-cancer Immune Atlas (iAtlas) to host the data and results derived from the PanCancerAtlas Immune Response Working Group and to provide external investigators witht the ability to reproduce results of the IRWG. Provide expertise related to the analyses of the metabolic and transcriptional regulatory networksand will work collaboratively to develop, implement, test, and benchmark all methods related to the dynamic analyses of the transcriptional regulatory and metabolic networks aimed at drug target discovery for Alzheimer's Disease. The Institute for Systems Biology will provide expertise related to the (dynamic) analyses of the metabolic and transcriptional regulatory networks and will work collaboratively to develop, implement, test, and benchmark all methods related to the dynamic analyses of the transcriptional regulatory and metabolic networks aimed at drug target discovery for the AMP-AD CC project. | |
| Icahn School of Medicine at Mount Sinai | ||||||||
| 1 Gustave L Levy Place | New York | NY | 11029 | 136171197 | $325,616 | $0 | Perform computational and integrative analysis of the AMP/AD data sets to develop a set of high probability therapeutic targets necessary for their assessment and integration into drug discovery efforts for the Agora project. Image-guided studies to determine the contribution of breast cancer cells to metastatic outgrowth Leukemias for the CSBC project. | |
| University of California San Diego | ||||||||
| 9500 Gilman Dr | La Jolla | CA | 92093 | 956006144 | $206,908 | $0 | To determine the test validity and test-retest reliability of smartphone-based measurement of CRF. To evaluate the feasibility and acceptability of using a smartphone application to measure CRF. This will be examined using a system usability scale and assessing compliance and overall satisfaction with the administered protocol. Provide expert consultation in the use of agile science methods for creating strategies for facilitating sustained engagement with the MPower 2.0 application. This includes providing expertise related to behavioral theory, human centered design, and measurement strategies. Develop an experimental design and broader strategy for gathering evidence to foster iterative improvement on mPower to foster improved sustained engagement with the tool. | |
| Stanford University | ||||||||
| 450 Serra Mall | Stanford | CA | 94305 | 941156365 | $175,960 | $0 | Oversee the genomic profiling, analysis, and computational modeling of metastatic colorectal cancer patient data. Prioritize candidate metastasisassociated genes and provide for modeling in organoids. Contribute to the analysis of cell fitness and clone size distributions in the metastatic colon organoid models. Interpret the data from the microenvironmental arrays. Create a baseline model for future comparison using existing framework for Digital Mammography Challenge. | |
| Fred Hutchinson Cancer Research Center | ||||||||
| 1100 Fairview Ave N | Seattle | WA | 98109 | 237156071 | $56,144 | $0 | Study the mechanisms that underlie metastatic castrate resistant prostate cancer(CRPC). We will combine approaches from pharmacology, as well as cell and computational biology to identify kinases that are functionally important for driving cell growth and proliferation in CRPC. We will employ Kinome regression approach to: (1) identify kinases in CRPC cell lines and patient-derived organoid models and test in silico predicted candidate kinase inhibitors in 3D bone-mimetic cultures; and (2) validate the effect of candidate kinase inhibitors in in vivo CRPC bone metastasis models, followed by molecular characterization. | |
| University of Pittsburgh | ||||||||
| 116 Atwood St | Pittsburgh | PA | 152133402 | 250965591 | $56,016 | $0 | Combine approaches from pharmacology, as well as cell and computational biology to identify specific kinases that are functionally important for the growth of metastatic CRPC. We will also build a computational model to predict response to >300 naive kinase inhibitors in a physiological-relevant CRPC bone metastasis model. Further, we will probe the spatial nature of the kinase-driven signaling patterns in the tumors, which is critical to understanding the mechanisms of drug response. Overall, these studies have a strong potential to advance medical practices; a new therapeutic option for metastatic CRPC could give unprecedented hope to the providers and patients who currently face this disease with severely limited alternatives. | Suite 201 |
| The University of Texas MD Anderson Cancer Center | ||||||||
| PO Box 4486 | Houston | TX | 77210 | 746001118 | $55,976 | $0 | Validate in 3D the top kinase inhibitors selected in the 2D screening. These experiments will be performed on up to 3 prostate cancer cellular models, including cell lines and patient-derived xenografts, testing different concentration of the inhibitors. | |
| Duke University | ||||||||
| 324 Blackwell St | Durham | NC | 277013659 | 560532129 | $52,160 | $0 | Metastasis is the primary cause of cancer patient mortality and is virtually uncurable. In colorectal cancer (CRC), which represents the third leading cause of cancer-related mortality in the United States, 10-20% of patients with Stage II disease and 50% with Stage III develop recurrence, while another 20% of patients present with metastases at diagnosis. Current targeted therapies for metastatic colorectal cancer (mCRC) prolong survival by mere months with little benefit in the adjuvant setting. Improved treatment strategies are thus urgently needed, but require characterization of the molecular drivers and microenvironmental determinants of the metastatic phenotype. Critically, the advent of advanced genome-engineering and lineage tracing technologies, 3-D organotypic culture systems and platforms to probe the tumor microenvironment provides an unprecedented opportunity for rapid, functional and phenotypic screens towards delineation of the genotype-phenotype map in cancer. | Ste 850 |
| Partners Healthcare System Inc | ||||||||
| 399 Revolution Dr | Somerville | MA | 021451465 | 270273715 | $47,732 | $0 | Combine mouse mammary cancer models with high-resolution imaging to quantify early vs late disseminated cancer cells, outgrown metastases, and their colocalization and dynamics. To quantify behavior of disseminated cancer cells using laser scanning confocal microscopy and other techniques available at the MGH Center for Systems Biology. | Ste 645 |
| University of Massachusetts Worcester | ||||||||
| 55 Lake Ave N | Worcester | MA | 016550002 | 043167352 | $46,255 | $0 | There is an ongoing debate concerning whether early DCCs or late DCCs drive metastasis during the life of a patient when both population will likely co-exist. We hypothesize that in fact both early and late disseminated cancer cells (DCCs) cooperate to drive metastatic outgrowth. Here, we adopt an innovative interdisciplinary approach combining metastatic tumor modeling, tissue engineering, high-resolution in vivo microscopy, and integrative omics analysis to tackle the problem. We believe the success of this pilot proposal will provide novel strategies to combat the deadly metastatic diseases, as well as foster our future collaborations. | |
| University of Arizona | ||||||||
| 220 W 6th St | Tucson | AZ | 85701 | 742652689 | $38,685 | $0 | The goal of the project is to develop small molecules (from in silico docking on the CD44 binding pocket and peptidomimetics of CD44 peptide) and peptides (from the peptide array) to disrupt the interaction between CD44 and FERM domain-containing proteins. These tools will help to define if the proteins are druggable, and whether targeting protein-protein interactions can have a more specific effects than global inhibition of the ectodomain of CD44 using antibodies or small molecules. This will pave the way to testing therapeutic hypotheses for AMP-AD targets relating to protein-protein interactions. | |
| Rutgers the State University of New Jersey | ||||||||
| 33 Knightsbridge Rd | Piscataway | NJ | 088543925 | 226001086 | $36,570 | $0 | The research proposal outlines image-guided studies to determine the contribution of breast disseminated cancer cells to metastatic outgrowth. | Room B112 |
| Oregon Health & Science University | ||||||||
| 3181 SW Sam Jackson Park Rd | Portland | OR | 972393908 | 931176109 | $21,269 | $0 | CSBC Pilot testing and optimization of MCAT/Her2 crainbow cells on MEMA platform and MEMA optimization and screening. | L106OPAM |
| San Ysidro Health | ||||||||
| 1601 Precision Park Lane | San Diego | CA | 92173 | 952801772 | $19,929 | $0 | San Ysidro Health (SYHealth) will participate in the "All of Us Research Program Sage Bionetworks - Federally Qualified Health Centers Consent Study" for participant recruitment and data collection. Findings from this study will be used immediately to improve, elaborate, and/or supplement AoURP informed consent materials for AoURP national launch. The project begins with formative work to determine study approach and contribute to study protocols and ends with data submission and analysis verification by the site PI. | |
| Hudson River Healthcare Foundation | ||||||||
| 1037 Main St | Peekskill | NY | 105662913 | 200151252 | $18,845 | $0 | Research Assistants (RAs) will recruit potential participants using a variety of techniques including engagement tabling in Barham House, a senior apartment building, at the Peekskill Kiley Center with the Community Action Program, and at local community venues like the Salvation Army, the Peekskill Library, and a local homeless shelter, in addition to health-center based recruitment. The RAs and Pilot Coordinator will liaise with community stakeholders to coordinate such recruitment efforts. Interested individuals are screened by RAs using the REALM-SF tool and, if eligible, invited to participate in a 1:1 interview or a focus group. Each session lasts approximately 1 hour and is facilitated and recorded by a Research Assistant. An additional RA participates for notetaking purposes as appropriate. In addition to these implementation activities, our PIs and Project Coordinators liaise with the other FQHCs involved, with Sage, and with MITRE to provide ongoing feedback on the REALM | |
| University of Rochester | ||||||||
| 500 Joseph C Wilson Blvd | Rochester | NY | 14627 | 160743209 | $7,667 | $0 | Provide consultation on interpretation and guidance on mPower 1.0 analysis and design and scientific strategy for mPower 2.0 data collection. | |
| New York University | ||||||||
| One Park Ave | New York | NY | 10016 | 135562308 | $5,677 | $0 | Data generation and analysis for the Proteogenomics Computational Challenge | 6th Floor |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 17 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule I, Part I, Line 2 | FormAndLineReferenceDesc |
| Explanation | In 2018, Sage Bionetworks issued grants, contributions, and prizes. Contributions were given in support of an awarded institution's project and prizes were awarded to research challenge winners. Monitoring the use of grant funds: In some cases, grants received by Sage Bionetworks are passed on to sub-recipients through a sub-award agreement. The Grant Manager is responsible for initiating the sub-award after obtaining budget approval from the PI and Operations Director. In issuing a sub-award, the Grant Manager is responsible for: obtaining verification of the sub-awardee's facilities and administrative rates and Single Audit Reports; reviewing the prime award special terms and conditions to determine whether they are applicable to the sub-award; and determining whether the sub-awardee meets all of the other administrative and regulatory requirements of the prime award. Once the sub-award has been issued, the Grant Manager is responsible for monitoring sub-award activity, including compliance with all reporting requirements. The Grant Manager is also responsible for forwarding the fully executed sub-award documents to the Accounting Manager to ensure proper billing. Payments are made only after the sub-award agreement has been fully executed by both parties. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| First Class Or Charter Travel | Yes (X) | FirstClassOrCharterTravelInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (11 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lara Mangravite | ||||||||||||||
| President | $245,496 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $36,644 | $0 | $282,140 | $0 | $0 | $0 |
| Diane Gary | ||||||||||||||
| Secretary | $166,446 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $30,837 | $0 | $197,283 | $0 | $0 | $0 |
| John Wilbanks | ||||||||||||||
| Chief Commons Officer | $231,848 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $21,981 | $0 | $253,829 | $0 | $0 | $0 |
| Mike Kellen | ||||||||||||||
| Chief Technology Officer | $210,759 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $23,947 | $0 | $234,706 | $0 | $0 | $0 |
| Justin Guinney | ||||||||||||||
| Vice President, Computational Oncology | $195,821 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $36,057 | $0 | $231,878 | $0 | $0 | $0 |
| Larsson Omberg | ||||||||||||||
| Vice President, Systems Biology | $166,446 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $30,832 | $0 | $197,278 | $0 | $0 | $0 |
| Bruce Hoff | ||||||||||||||
| Director, Synapse Team | $166,334 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $39,614 | $0 | $205,948 | $0 | $0 | $0 |
| Erin Mounts | ||||||||||||||
| Principle SW Engineer | $161,735 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $30,504 | $0 | $192,239 | $0 | $0 | $0 |
| Dwayne Jeng | ||||||||||||||
| Principal SW Engineer | $156,897 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $19,987 | $0 | $176,884 | $0 | $0 | $0 |
| Alx Dark | ||||||||||||||
| Principle Software Engineer | $156,811 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $11,529 | $0 | $168,340 | $0 | $0 | $0 |
| John Woodburn | ||||||||||||||
| Director, Design | $154,830 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $19,835 | $0 | $174,665 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Schedule J, Part I, Line 1a | All travel conducted per the company travel policy. |
| Schedule J, Part I, Line 3 | Setting executive compensation is the responsibility of the Board of Directors Compensation Committee. |
Schedule M IRS990ScheduleM
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form8283 Received | 0 | Form8283ReceivedCnt |
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | 0 | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule M, Part I, Line 33 | FormAndLineReferenceDesc |
| Explanation | Received In-Kind legal services. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (5 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Form 990, Part VI, Section B, Line 11b | The 990 is reviewed by the company's Vice President of Operations and President prior to filing. |
| Form 990, Part VI, Section B, Line 12c | Sage Bionetworks has a Financial Conflict of Interest Policy (FCOI) that complies with the National Institutes of Health-specific requirements promoting objectivity in research, 42 CFR Part 50 subpart F. On an annual basis, Sage Bionetworks Officers, Directors, and members of committees of Board of Directors authorized to act on behalf of the board, and employees designated by the President of Sage Bionetworks, including any employees serving as an investigator on a federal/Public Health Services award, must review and update the Sage Bionetworks Annual Conflict of Interest Questionnaire. New employees serving as investigators are required to complete a FCOI form within 30 days of their start date. In addition, all investigators must submit an ad hoc disclosure of a Significant Financial Interest they acquire or discover during the course of the year within 30 days of discovering or acquiring the Significant Financial Interest. Forms are reviewed and any potential conflicts are referred to the President and outside counsel. |
| Form 990, Part VI, Section B, Line 15 | Executive compensation was set by the Board of Directors Compensation Committee. |
| Form 990, Part VI, Section C, Line 19 | The organization's financials are contained within its 990 returns. These returns are available to the public through organizations such as Guidestar, dedicated to publicizing information about nonprofit organizations. The organization's governing documents and conflict of interest policies are available upon request. |
| Form 990, Part IX, Line 11g | Scientific Reseach Expenses $1,109,936; Assembly Expenses $179,475; Platform/Scientific Computing Expenses $847,697; Professional Services Expenses $235,191. |
Reasonable Cause Explanation ReasonableCauseExplanation
| Field | Value | IRS element (for citing) |
|---|---|---|
| Explanation | CPA Single Audit was not completed until the end of September. | ExplanationTxt |
Comments